Metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models
Top Cited Papers
- 26 January 2026
- journal article
- review article
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 23 (4) , 286-317
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses liver steatosis and metabolic dysfunction-associated steatohepatitis (MASH), which can result in fibrosis and/or cirrhosis and increase the risk of hepatocellular carcinoma (HCC). The latest Clinical Practice Guidelines acknowledge the importance of systemic metabolic dysfunction as a driver of hepatic lipid accumulation and disease progression. To ensure translational relevance of preclinical models, they need to faithfully replicate the key human pathophysiological characteristics of MASLD and its progression to fibrosis and HCC. This Review discusses the strengths and weaknesses of prevalent MASLD and MASH-HCC preclinical models, expanding the discussion to the latest advances in vivo (for example, genetically altered, humanized and large animals) and in vitro (for example, organoids or spheroids, 3D-bioprinted livers, precision-cut liver slices, organs-on-a-chip and decellularized scaffolds). Evidence will be critically re-assessed according to the new MASLD definition, paving a consensus in the field for nomenclature, expected limitations and how to conduct a systematic validation of new models against human-relevant disease outcomes. We also propose a standardized pipeline for preclinical studies in MASLD and MASH-HCC. This Review aims to help researchers make informed decisions when choosing an experimental design that best aligns with the specific requirements of their projects, whilst meaningfully replicating human disease.Keywords
This publication has 438 references indexed in Scilit:
- Protection against Western diet–induced obesity and hepatic steatosis in liver fatty acid–binding protein knockout miceHepatology, 2006
- Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosisJournal of Gastroenterology, 2006
- Fat Aussie—A New Alström Syndrome Mouse Showing a Critical Role for ALMS1 in Obesity, Diabetes, and SpermatogenesisMolecular Endocrinology, 2006
- Capturing complex 3D tissue physiology in vitroNature Reviews Molecular Cell Biology, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomasJournal of Clinical Investigation, 2004
- Initial sequencing and comparative analysis of the mouse genomeNature, 2002
- Culture matrix configuration and composition in the maintenance of hepatocyte polarity and functionBiomaterials, 1996
- Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha.Proceedings of the National Academy of Sciences, 1994
- Reciprocal modulation of growth and differentiated functions of mature rat hepatocytes in primary culture by cell--cell contact and cell membranes.Proceedings of the National Academy of Sciences, 1983